Page 4 - Pharma Stocks

New product launches to drive growth for Lupin, US business a key trigger

This should reverse the US underperformance in FY15-20 with margins too moving up sharply

Apollo Hospitals opens QIP with floor price of Rs 2,508.58 a share

Sources said that the hospital chain is targeting large Domestic Mutual Funds, Sovereign Funds

Select pharma shares rally; Suven Pharma up 13%, Laurus nears record high

Healthcare companies to post decent growth in revenues in Q3FY21

Limited near term gains for Syngene International stock in pharma space

Sharp re-rating has turned the stock into the most expensive in the pharma space

Gland Pharma's growth trajectory to remain elevated in medium term

Margin expansion to support profits, clean regulatory track record to help sustain growth journey

Nifty Pharma index hits new record high; Laurus Labs, Glenmark Pharma up 3%

Cipla, Cadila Healthcare, Lupin, Sun Pharma and Aurobindo Pharma from the Nifty Pharma index were up in the range of 1 per cent to 2 per cent on the NSE

Lupin rises on settling dispute with Gavis and Novel; gains 5% in four days

On Wednesday, Lupin announced in a BSE filing that its dispute with the sellers in the Gavis and Novel transaction has been resolved amicably to the satisfaction of all parties.

Chronic portfolio may help Cipla sustain growth outperformance in near term

Margin gains in the September quarter too are expected to continue

Pharma shares in focus; Divi's Labs hits new high, Gland Pharma zooms 20%

Dishman Carbogen Amcis, Ipca Lab, SPARC, Caplin Point Laboratories, Dr. Lal PathLabs and Granules India from the S&P BSE Healthcare index were up in the range of 4 per cent to 5 per cent on the BSE

'Banking sector a good long-term bet despite expensive valuation'

The market expects a strong bounce in earnings growth in FY22 with a growth of more than 30 per cent on a YoY basis.

IT, pharma firms emerge Samvat 2076 winners; Infy, Divi's Lab top gainers

On the other hand, PSU stocks and banks have been laggards - with ONGC, Indian Oil, IndusInd Bank, and Coal India delivering the worst returns.

Divi's Lab, Aurobindo Pharma: Are pharma stocks losing their sheen? Read on

Till Nifty Pharma holds above the 11,180 mark, the bullish bias will prevail, charts suggest.

Tata Motors to Bharat Forge: Stock winners and losers in India from US Vote

Here are some key things to watch in India with respect to the upcoming US vote

Divestment of US subsidiary to leave Aurobindo Pharma cash positive

Divestment of the US subsidiary is at good valuations and will help attain net cash positive status

Edelweiss's healthcare fund offers benefit of international diversification

Allocation to a thematic offering like the newly-launched healthcare index fund should, however, be limited

GSK Pharma's growth challenges to remain in near term as Covid dents sales

Even as overall pharma market was up 5% over the year-ago period, GSK's September sales were down 8%, the firm is banking on recovery led by top brands, new launches

Kopran hits 52-week high after Crisil upgrades rating outlook to 'Positive'

The rating agency reaffirmed its 'CRISIL BBB' rating on long term bank facilities, while short term ratings has been reaffirmed at 'CRISIL A3+'

Pharma stocks gain; Cipla hits record high, Lupin nears 52-week high

In the past month, Cipla and Lupin outperformed the market by gaining 12 per cent each, against 8 per cent rise in Nifty Pharma index

Solara Active Pharma surges 19% on heavy volumes, hits record high

Global brokerage Macquarie Capital Securities, on October 6, initiated coverage on the stock with an 'Outperform' rating and a target price of Rs 2,064 in bull-case scenario

IT stocks are a good bet even at the current levels: Naveen Kulkarni

IT stocks were expected to re-rate and that is happening now.